Cardiovascular Risk Factors / Randox News

Randox licenses sPLA2 cardiovascular disease (CVD) risk test from Aterovax

Randox licenses cardiovascular disease (CVD) risk test from AterovaxRandox Laboratories Ltd., a privately owned UK diagnostic company with an extensive portfolio of diagnostic markers for Cardiovascular disease (CVD) and Aterovax SA, a privately owned French diagnostic company focused on the development and commercialisation of novel cardiovascular diagnostics have announced a strategic partnership to commercialise Aterovax’s patented biomarker secreted Phospholipase A2 (sPLA2) for the assessment of cardiovascular risk. Terms of the alliance were not disclosed.

sPLA2 is a novel biomarker that independently and over and above traditional risk factors predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome.

Randox have exclusive rights to develop, manufacture and market the new test for use on automated immunoassay analysers and will develop the sPLA2 test for its own range of analysers and other diagnostic analysers.

Dr. Peter FitzGerald CBE FREng, Managing Director at Randox commented “this was an exciting opportunity for Randox to expand its portfolio of CVD biomarkers and demonstrates continued investment in this field. The new SPLA2 test has been shown to add significant clinical value when combined with other biomarkers in the Randox range of tests and offers us the opportunity to provide an effective panel of tests for CVD risk assessment with strong clinical utility. The sPLA2 test will be offered to hospital laboratories through our global distribution network in 145 countries”

Dr. Gerald Ulrich, CEO of Aterovax believes this strategic partnership will utilize the strengths of Aterovax’s many years research in CVD, especially on the development, role and clinical utility of its patented biomarker (sPLA2) in CVD risk assessment/patient stratification with Randox’s expertise in developing assays for automated immunoassay platforms and “pioneering” novel new assays in CVD biomarkers to establish a sustainable market presence for sPLA2 in the global clinical laboratory market for CVD risk assessment.

Line

About Randox Laboratories Ltd.

Randox is a global market leader within the in vitro diagnostics industry, developing innovative diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. With offices and distribution in over 145 countries, Randox offers customers improved efficiency, quality, cost-effectiveness and flexibility. Randox is committed to revolutionising healthcare on a global scale. With over 1000 employees globally, Randox is dedicated to meeting your testing needs.

Line

About Aterovax Laboratory

Aterovax is developing innovative diagnostic products for the cardiovascular disease market based on a unique understanding of atherosclerosis, the condition responsible for most cardiovascular problems.  Aterovax is currently investigating the role of additional new biomarkers involved in atherosclerosis.  The company, stemming from the French academic research, was founded in Paris, France in 2006 with financing from the SEFTI fund.  This specialist European cardiovascular fund has been joined by two new partners in 2012, FA DIESE and Turenne Captial Partenaires.

Leave a Reply

Your email address will not be published. Required fields are marked *

*